Contents

Current Cancer Drug Targets, Volume 16 - Number 4

Meet Our Editorial Board Member:

, 16(4): 287

Evan Keller


DOI: 10.2174/156800961604160408203704




Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin

, 16(4): 288 - 304

Zhipeng Zou, Juan Chen, Jun Yang and Xiaochun Bai


DOI: 10.2174/1568009616666151113120830





A New Therapeutic Era in GCB and ABC Diffuse Large B-cell Lymphom a Molecular Subtypes: A Cell of Origin-Driven Review

, 16(4): 305 - 322

Jose D. Sandoval-Sus, Julio Chavez and Samir Dalia


DOI: 10.2174/1568009615666151030102539





New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia

, 16(4): 323 - 345

Rui Huang, Qian Kang, Huimin Liu and Yuhua Li


DOI: 10.2174/1568009615666150921141004





Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer

, 16(4): 346 - 356

Xue-Qing Hu, Yang Sun, Eric Lau, Ming Zhao and Shi-Bing Su


DOI: 10.2174/1568009616666151207105851





Development of Linker-Conjugated Nanosize Lipid Vesicles: A Strategy for Cell Selective Treatment in Breast Cancer

, 16(4): 357 - 372

Niladri Shekhar Dey, Biswajit Mukherjee, Ruma Maji and Bhabani Sankar Satapathy


DOI: 10.2174/1568009616666151106120606





Epigallocatechin-3-gallate Increases RXRγ-mediated Pro-apoptotic and Anti-invasive Effects in Gastrointestinal Cancer Cell Lines

, 16(4): 373 - 385

Alessio Papi, Marzia Govoni, Carmen Ciavarella, Enzo Spisni, Marina Orlandi and Fulvia Farabegoli


DOI: 10.2174/1568009615666150817120931





Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science